Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
215,820

+2.51 (2.98%)

Updated Jul 8, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

LGND or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. RGEN: Which Stock Is the Better Value Option?

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

by Zacks Equity Research

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.

Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease

by Zacks Equity Research

Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.

Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.

Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD

by Zacks Equity Research

Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.

Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing

by Zacks Equity Research

Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.

Gilead to Buy 49.9% Stake in Private Biotech for $275M

by Zacks Equity Research

Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.

Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan

by Zacks Equity Research

The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag

by Zacks Equity Research

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.

LGND or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. RGEN: Which Stock Is the Better Value Option?

ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis

by Zacks Equity Research

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

Immunic Gets FDA Allowance for Phase II Coronavirus Study

by Zacks Equity Research

Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.

Vertex's Kalydeco Wins Approval in EU for CF in Children

by Zacks Equity Research

Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.

Why Is Ligand (LGND) Up 16.3% Since Last Earnings Report?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. TECH: Which Stock Is the Better Value Option?

Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LGND vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LGND vs. TECH: Which Stock Is the Better Value Option?

Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View

by Zacks Equity Research

Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.

Ligand Pharmaceuticals (LGND) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Ligand (LGND) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.

Ligand (LGND) Up 16.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.

Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?